CC
RLMD icon

Commodore Capital’s Relmada Therapeutics RLMD Stock Holding History

Commodore Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.86M Buy
1,425,000
+791,099
+125% +$5.53M 0.59% 28
2026
Q1 		$4.41M Buy
+633,901
New +$3M 0.26% 36
2021
Q2 		– Sell
-161,565
Closed -$5.69M – 30
2021
Q1 		$5.69M Sell
161,565
-17,000
-10% -$595K 2.27% 19
2020
Q4 		$5.73M Buy
+178,565
New +$6.14M 3.11% 17

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commodore Capital's RLMD Position: Q2 2026 in Review

Commodore Capital increased its Relmada Therapeutics (RLMD) stake by 125% in Q2 2026, buying an estimated $5.53M and bringing the position to 1,425,000 shares worth $9.86M. The position accounts for 0.59% of the portfolio, ranked #28.

Commodore Capital first reported a position in RLMD in Q4 2020 and has held it in 4 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Commodore Capital held 1,425,000 shares of Relmada Therapeutics worth $9.86M as of Q2 2026.
  • Commodore Capital bought 791,099 Relmada Therapeutics shares in Q2 2026, an estimated $5.53M.
  • Relmada Therapeutics made up 0.59% of Commodore Capital's portfolio in Q2 2026, its #28 holding.
  • Commodore Capital first reported a position in Relmada Therapeutics in Q4 2020 and has held it in 4 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.